## Edgar Filing: GenMark Diagnostics, Inc. - Form 4

| GenMark Diagnostics, Inc.       Form 4         February 22, 2016       OMB APPROVAL         FORM 4       UNITED STATES SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549       OMB APPROVAL         Check this box<br>if no longer<br>subject to<br>Section 16.<br>Form 4 or<br>Form 5<br>obligations<br>may continue.<br>See Instruction<br>1(b).       STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF<br>SECURITIES       OMB Methods         Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,<br>obligations<br>may continue.<br>See Instruction<br>1(b).       Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,<br>outpen hours per<br>esponse       Statement Company Act of 1935 or Section<br>30(h) of the Investment Company Act of 1940         (Print or Type Response)       (Print or Type Response)       Statement Company Act of 1940 |                  |   |   |                         |          |   |  |                 |  |  |
|--|------------------|---|---|-------------------------|----------|---|--|-----------------|--|--|
| Kayyem Jo  |                  | Symbol<br>GenMa   | 2. Issuer Name <b>and</b> Ticker or Trading<br>Symbol<br>GenMark Diagnostics, Inc. [GNMK] |                         |          |   | <ul><li>5. Relationship of Reporting Person(s) to Issuer</li><li>(Check all applicable)</li></ul>  |                 |  |  |
| (Last)<br>5964 LA P  | (First) (Middle) | (Month/E  | 3. Date of Earliest Transaction<br>(Month/Day/Year)<br>02/18/2016                         |                         |          |   | Director       10% Owner         Officer (give title       Other (specify below)         SVP, Research & Development   |                 |  |  |
| CARLSBA  |                  | Amendment, Date Original<br>Month/Day/Year)                 |   |                         |          | <ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> <li>Person</li> </ul> |  |                 |  |  |
| (City)   | (State) (Zip)    | Tabl  | le I - Non-I  | Derivative S            | Securi   | ties Ac   | quired, Disposed   | of, or Benefici | ally Owned                                     |  |
| 1.Title of<br>Security<br>(Instr. 3)   | any              | nsaction Date 2A. Deemed<br>th/Day/Year) Execution Date, if |   |                         |          | quired<br>of  | 5. Amount of<br>Securities Ownership<br>Beneficially Form: Direct<br>Owned (D) or<br>Following Indirect (I)<br>Reported (Instr. 4)<br>Transaction(s)<br>(Instr. 3 and 4) |                 | 7. Nature of<br>Indirect                       |  |
| Common<br>Stock  | 02/18/2016       |   | Code V<br>A   | Amount<br>53,287<br>(1) | (D)<br>A | Price<br>\$ 0   | 155,181  | D               |  |  |
| Common<br>Stock  |                  |   |   |                         |          |   | 61,651   | I               | HI<br>Charitable<br>Remainder<br>Uni Trust (2) |  |
| Common<br>Stock  |                  |   |   |                         |          |   | 569,308  | I               | IFIN LP (2)                                    |  |
| Common<br>Stock  |                  |   |   |                         |          |   | 82,934   | I               | The Jon<br>Faiz<br>Kayyem and                  |  |

|   |   |   |   |                            |  |  |                    | Paige N<br>Gates<br>Family<br>Trust, c<br>April 1<br>2000 ( <u>2</u> | lated   |    |  |  |
|---|---|---|---|----------------------------|--|--|--------------------|--|---|----|--|--|
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.<br>Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |   |   |   |                            |  |  |                    | SEC 1474<br>(9-02)   |   |    |  |  |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)  |   |   |   |                            |  |  |                    |  |   |    |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, i<br>any<br>(Month/Day/Year | Code                       | 5. Number of<br>orDerivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | erivative Expiration Date<br>ecurities (Month/Day/Year)<br>cquired (A)<br>r Disposed of<br>D)<br>nstr. 3, 4, |                    |  | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |    |  |  |
|   |   |   |   | Code V                     | (A) (D   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares                                 |    |  |  |
| Market<br>Stock<br>Units  | \$ 0  | 02/18/2016                              |   | А                          | 17,780<br>( <u>3</u> )   | <u>(4)</u>   | <u>(4)</u>         | Common<br>Stock  | 17,780<br>(3)   | \$ |  |  |
| Reporting Owners  |   |   |   |                            |  |  |                    |  |   |    |  |  |
| Reporting   | Owner Name  | e / Address<br>Directo                  | r 10% Owner   | <b>Relation</b><br>Officer | ships  |  | Other              |  |   |    |  |  |

Kayyem Jon Faiz 5964 LA PLACE COURT CARLSBAD, CA 92008

SVP, Research & Development

## Signatures

/s/ Eric Stier, Attorney-in-fact <u>\*\*</u>Signature of Reporting Person Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: GenMark Diagnostics, Inc. - Form 4

The amount reported reflects restricted stock units granted to the reporting person pursuant to the Issuer's 2010 Equity Incentive Plan. The (1) restricted stock units vest 25% on February 1, 2017 and the remaining shares subject to such award vest in 12 equal quarterly installments thereafter.

Dr. Kayyem is the trustee of the HI Charitable Remainder Uni Trust, trustee of The Jon Faiz Kayyem and Paige N. Gates Family Trust,
(2) dated April 1, 2000 and the President of In-Motion LLC, the general partner of IFIN LP. Dr. Kayyem disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.

Each market stock unit ("MSU") represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upper vertice of the MSUs if any is based on the Issuer's total shoreholder ratum for each performance period as commoned to the Needer

(3) Issuer's common stock, subject to the level of achievement of appreade performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index.

The MSUs vest in three equal installments, on each of December 31, 2016, December 31, 2017, and December 31, 2018; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in

(4) the end of the second and unit annual performance periods, the Reporting Person is engipte to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.